Amplia Therapeutics Limited (ASX: ATX, “Amplia”) has released a new investor presentation which provides an update on the Company’s technology and its near-term and mid-term plans as it moves towards initiating its first clinical trial later this year.
To see the presentation in full, please click the link below.
“The company has made extraordinary progress over the last 12 months and it is very exciting to be on the cusp of commencing the clinical development of AMP945. The Phase 1 trial we plan to conduct has been designed to unlock the commercial opportunities provided by AMP945 and we expect to hit several key development milestones over the next 12-18 months”.
Open an account with an online broker of your choice. If you do not have an existing broker, consider Mawson Graham's A$9.50 flat fee platform.
Sign up now »Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.
